Centre of Research Excellence for the Study of Naevi Launch and Consumer Forum
To view presentations from this event please click here.
For Media coverage of this event please click here.
The Centre of Research Excellence for the Study of Naevi will launch with a Consumer Forum on Tuesday 26 April. The launch will bring together world-leading researchers, consumers (melanoma patients and their friends and families) and consumer organisations, especially the Cancer Council Queensland and Melanoma Patients Australia, to talk about the research aims of the Centre of Research Excellence.
Prof H. Peter Soyer, Chair in Dermatology and Director, Dermatology Research Centre, The University of Queensland, will lead a team of collaborators from the QIMR Berghofer Medical Research Institute, Cancer Council Queensland, The University of Sydney, and the Queensland University of Technology in the new Centre of Research Excellence for the Study of Naevi. The CRE is funded by the Australian Government National Health and Medical Research Council (NHMRC) until the end of 2020.
Melanoma is the third most commonly diagnosed cancer in both men and women in Australia, currently affecting more than 12,500 Australians each year. The incidence of melanoma in Australia continues to increase, with the highest rates in Queensland, the ‘Melanoma Capital of the World’. This CRE for the Study of Naevi is taking an innovative approach to studying melanoma tumorigenesis by examining naevi, the benign lesions (or moles) of the skin. Studies have consistently shown that number of naevi is the strongest predictor of risk for melanoma, with many melanomas growing adjacent to or within pre-existing naevi. An improved understanding of naevi development, transformation and recognition of changes, is key to understanding melanoma and establishing more efficient prevention and early detection models for this common malignancy.
The team expects that the combined results from the CRE for the Study of Naevi will ultimately contribute to personalised medicine via risk stratified naevi prevention and surveillance programs, leading to improved professional and consumer education materials, and inspire young clinicians and scientists to use the latest technological advances in skin cancer diagnostics.